RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow
NOKOMIS, Fla. -- April 02, 2013
Last week, Rainbow BioSciences, the biotechnology division of Rainbow Coral
Corp. (OTCBB: RBCC), unveiled a new website highlighting its explorations into
the multi-billion-dollar drug delivery and genome-mapping market.
To view the new website, please visit www.rainbowbiosciences.com.
In particular, the revamped site details the company’s new partnership with
TheraKine Ltd., the developer of a revolutionary, sustained-release drug
delivery platform that could soon make local delivery of biologic agents and
small molecules safer, more effective and more convenient than ever before.
Some experts believe that the worldwide market for the 10 most popular drug
delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.
In addition, RBCC is close to partnering with a cutting-edge genome-mapping
facility in Houston capable of helping doctors assess genetic variations in
patients in order to create more effective, optimized drug treatment plans.
The genetic testing sector is one of the fastest-growing segments of the
global biotech industry, with some market experts expecting it to reach $2.2
billion by 2017.
“The partnerships that we’re targeting could help usher in a new era of
healthcare: personalized medicine,” said RBCC CEO Patrick Brown. “We see big
growth in store for this sector, and Rainbow BioSciences’ improved website
will help us keep shareholders, potential investors and other interested
parties up to date on our latest activities to bring these revolutionary
technologies to a pharmacy or clinic near you.”
Rainbow BioSciences is dedicated to developing and marketing new medical and
research technologies to compete in a fast-growing industry alongside
companies such as Bristol Myers Squibb Co. (NYSE:BMY),Biogen Idec Inc.
(NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT) and Valeant Pharmaceuticals
International (NYSE: VRX).
For more information on these initiatives, please
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visitwww.RainbowBioSciences.com. For investment information and
performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
Press spacebar to pause and continue. Press esc to stop.